Health and Healthcare

WebMD Extends Poison Pill for Two More Years

WebMD Health Corp. (NASDAQ: WBMD) said that on Thursday its board of directors has signed off an amendment to its shareholder rights agreement to guard against coercive takeovers and other tactics that might be used in attempts to gain control of the company.

The amendment does the following:

  • Extends the expiration date of the Rights Agreement from October 31, 2012, to October 31, 2014
  • Provides that equity compensation awards to directors will not be included in determining whether a stockholder becomes an “Acquiring Person” under the Rights Agreement
  • Decreases the purchase price payable by holders of rights issued under the Rights Agreement upon exercise of such rights from $153.00 to $66.29.

The amended rights agreement will be presented for ratification at the 2013 annual meeting of WebMD stockholders.

WebMD adopted the poison pill agreement back in early November in response to billionaire investor Carl Icahn pushing the company to spend up to $1 billion to buy back its shares. Icahn is a leading shareholder in the online health information provider, and he successfully got an appointee onto the board after the previous shareholder meeting in July.

WebMD has long been considered a takeover target, but the company’s efforts to sell itself ended early this year after talks with private equity firms failed. The share price has dropped about 63% year to date, and it is down fractionally in morning trading to $14.20. The 52-week low is $13.52.

Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)

Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.

Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.

Click here now to get started.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.